TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri
Brief Summary: Aim: to assess relative effectiveness of a high and a low intensity intervention for smoking cessation support in a dental clinic setting.

Method: 300 smokers were randomly assigned to support with either low (LTI) or high treatment intensity (HTI).

Main outcome measures were self-reported point-prevalence and continuous abstinence (≥183 days).


Options:
A: Inclusion Criteria:

* Age 18 years and older
* Smoke at least once a day for the past 30 days
* Are willing to participate in all study components
* Sufficient language skills in English for counseling and assessments
* Has a home address
* Has a working phone number

Exclusion Criteria:

* Pregnant or planning to become pregnant in the next 6 months
* Currently using a smoking cessation medication
* Currently participating in smoking cessation program
* Motivated to quit smoking
* Planning to quit smoking in the next 2 weeks
* Lives in a home with someone currently enrolled in the study
* Minor
B: Inclusion Criteria:

* Be receiving care for HIV at one of the participating immunology clinics
* Be 18 years old or older
* Be current (past 7 days) cigarette smoker
* Speak English or Spanish

Exclusion Criteria:

* Are pregnant or nursing
* Have uncontrolled hypertension
* Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help with quitting smoking
* Are allergic to the nicotine patch or have a skin condition like eczema or psoriasis that makes them unable to use the patch
C: Inclusion Criteria:

* Age 18 and older
* Daily smokers over the past 30 non-institutionalized days (prior to Incarceration)
* Expected place of residence after release within 15 miles of follow-up site
* Agree to participate in the study protocol and be available within one month post release
* Speak English
* Provides at least two pieces of locator information
* Scheduled to be released within eight weeks

Exclusion Criteria:

* Inability to give informed consent secondary to organic brain function, not having own legal guardianship, or active psychosis or otherwise not able to participate in the intervention or assessments (deaf, blind, or impaired communication skills that impair ability to participate in computerized assessment or counseling)
* Housed in a segregation unit
D: Inclusion Criteria:

* Adult daily smokers in the county of Västmanland

Exclusion Criteria:

* Reading difficulties
* Not fluent in the Swedish language

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
Brief Summary: Recent studies indicate that infusing 300 milliliters of water (in lieu of air) into the rectum and left colon through the colonoscope as it is being inserted during a colonoscopy examination can allow easier endoscope advancement. This method may prevent stretching of the colon, and ultimately reduce pain induced during colonoscopy. Improvements in patient comfort and cooperation, may increase the efficiency and success rate of complete colonoscopy. The purpose of the study is to test the efficacy of the water immersion technique in patients colonoscopy.


Options:
A: Inclusion Criteria:

* healthy individual 50 years or older
* eligible for colorectal cancer screening or surveillance

Exclusion Criteria:

* patients who do not understand or failed to sign informed consent
B: Inclusion Criteria:

* Patients with prior abdominal or pelvic surgery,

Exclusion Criteria:

* History of colorectal surgery
* Severe colonic stricture or obstructing tumor
* Patients who cannot give informed consent and those who are hemodynamically unstable
C: Inclusion Criteria:

* Patients undergoing minimally sedated colonoscopy

Exclusion Criteria:

* Obstructive lesions of the colon, inadequate bowel preparation, allergy to meperidine, massive ascites, past history of partial colectomy, or refusal to provide written informed consent.
D: Inclusion Criteria:

* presentation for colonoscopy
* male
* age 18 or older

Exclusion Criteria:

* women
* known inflammatory bowel disease
* presentation for emergency colonoscopy
* history of partial colectomy
* chronic narcotic or benzodiazepine use

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Combined Analyses and Long-term Follow-up in the Two Norwegian Homocysteine-Lowering B-Vitamin Trials NORVIT and WENBIT
Brief Summary: Two large homocysteine-lowering B-vitamin intervention trials have been performed in Norway during the period 1998 to 2005, NORVIT and WENBIT. The main objective in these trials was to study the clinical effects of homocysteine-lowering therapy with folic acid and vitamin B12 in patients with established coronary artery disease. Follow-up was terminated for NORVIT on Marc 31st 2004 and for WENBIT October 5th 2005, and none of the two trials proved any protective effect of the B-vitamin intervention on cardiovascular outcomes.

There is so far no data on possible long-term effects following years of such B-vitamin treatment.

Thus, the main objective of the combinded NORVIT-WENBIT study will will be to evaluate the long-term effect of the B-vitamin intervention on incident life-style diseases including cardiovascular disease, diabetes, osteoporotic fractures and cancer.

A secondary object will be the identification of risk phenotypes or genotypes, and if such risk associations are midified by the B-vitamin intervention


Options:
A: Inclusion Criteria: healthy women ages 55 and older who were at least four years postmenopausal living independently in a nine-county rural area of Nebraska

-

Exclusion Criteria:

1) chronic kidney disease, 2) Paget's metabolic bone disease, and 3) history of cancer except for superficial basal or squamous cell carcinoma of the skin and

-
B: Inclusion Criteria:

* Randomised in the Norwegian Vitamin Trial (NORVIT) or in the Western Norway B-Vitamin Intervention Trial (WENBIT)

Exclusion Criteria:

* Withdrawn consent to participate in study cohort for post-trial observational follow-up
C: Women, aged 40 and over, at high risk, with a history of cardiovascular disease or three or more coronary heart disease risk factors.
D: Inclusion Criteria:

* Age: ≥ 55 years
* Last menstrual period (LMP): ≥ 4 years
* Good general health
* Willingness to participate in this 4 year long study
* Able to give informed consent
* Able to live independently and travel to the Fremont Area Medical Center (FAMC) for study visits

Exclusion Criteria:

* History of cancer except

  * Superficial basal or squamous cell carcinoma of the skin
  * Other malignancies treated curatively more than 10 years ago
* History of renal calculi or chronic kidney disease
* History of sarcoidosis
* History of tuberculosis
* Participation in the previous Creighton cancer prevention study
* Mini-Mental Status Exam (MMSE) score of ≤ 23. Use the MMSE if there are any concerns about the person's cognitive abilities or ability to give fully informed consent to the study. Concerns may be related to a person's lack of orientation to person, place, or time; language difficulties (inability to structure simple, complete sentences); or short term memory. The Hartford Institute for Geriatric Nursing recommends that a score of 23 or lower indicates cognitive impairment. (Accessed at www.harforddign.org). See appendix.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.
Brief Summary: The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.


Options:
A: Inclusion Criteria:

* Osteoporotic patients (T score ≤ -2.5) with advanced prostate cancer requiring hormone manipulation, due to biochemical relapse following either radical prostatectomy, radiotherapy, brachytherapy, or biochemical progression after initially being observed with prostate cancer.

Exclusion Criteria:

* Severe hepatic insufficiency, with bilirubin above reference range
* Previous systemic therapy for prostate cancer
* Radiotherapy within 6 months
* Previous other invasive malignancies
* Any severe concomitant disease.
B: Inclusion Criteria:

* Clinical diagnosis of non-metastatic cancer of the prostate gland
* Patient to be 18 years and above

Exclusion Criteria:

* Previous systemic therapy for prostate cancer
* Previous history of another form of cancer (not prostate) within 5 years of study start.
C: Inclusion Criteria:

* Clinical diagnosis of non-metastatic cancer of the prostate gland
* Patient to be 18 years and above

Exclusion Criteria:

* Previous systemic therapy for prostate cancer
* Previous history of another form of cancer (not prostate) within 5 years of study start.
D: Inclusion Criteria:

* Prostate cancer in the early stage of disease
* Prostate removed and/or radiation therapy to the prostate area

Exclusion Criteria:

* Previous systemic therapy for prostate cancer
* Previous history of another form of cancer (not prostate) within 5 years of study start.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Promoting Colon Cancer Screening Among African Americans
Brief Summary: RATIONALE: An interactive computer program may be more effective than a brochure in increasing colorectal cancer screening among African Americans.

PURPOSE: This randomized clinical trial is studying an interactive computer program to see how well it works compared with a brochure in increasing colorectal cancer screening among African Americans.


Options:
A: Inclusion Criteria:

* Members of the Henry Ford Health System

Exclusion Criteria:

* Individuals who are not members of the Henry Ford Health System
B: Inclusion Criteria:

* Primary care patients aged 18 and older, of participating physicians within 5 internal medicine practices in Boston
* Registered users of patient-provider internet portal called PatientSite
* Screened positive for depression, chronic pain, or lower extremity mobility difficulty

Exclusion Criteria:

* Current treatment for screened condition by medical or surgical specialist or other appropriate licensed health professional such as a physical therapist or mental health counselor
C: DISEASE CHARACTERISTICS:

* Currently being seen in the primary care clinics of Wishard Memorial Hospital (Indianapolis, IN), Roudebush Veterans Affairs Medical Center (Indianapolis, IN), IU Health Family Medicine Center (Indianapolis, IN) or Norton Louisville Primary Care Clinic (Louisville, KY)
* African-American who is currently non-adherent to screening guidelines, meeting all of the following criteria:

  * No fecal occult blood test in the past 12 months
  * No sigmoidoscopy in the past 5 years
  * No colonoscopy in the past 10 years
* Patients with average and increased risk for colorectal cancer are eligible
* No personal history of colorectal cancer

PATIENT CHARACTERISTICS:

* Participants must have a telephone
* English-speaking
* Able to read at a 5th grade reading level
* No medical condition that prohibits colorectal cancer screening

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
D: Inclusion Criteria:

* Established T1D diagnosis for a minimum of one year (chosen to allow time for adjustment to a new diagnosis and more stable disease control).
* Between the ages of 17 and 20 years. It is left to the clinical judgment of the pediatric endocrinologist to determine individually the appropriate age of the transition for each subject
* At least 1 visit during the previous year with the pediatric endocrinologist at a Diabetes Clinic (aim is to minimize the non-adherence with the intervention).
* Ability to participate in all aspects of this clinical trial.
* Written informed consent/assent must be obtained and documented.
* Resident of Ontario.

Exclusion Criteria:

* Pregnant or lactating females or intent to become pregnant during the next 3 years.
* Conditions which in the opinion of the investigator may interfere with the subject's ability to participate in the study.
* Prior enrollment in the current study.
* Current participation in another clinical trial or participation in another clinical trial in the 6 months prior to enrollment.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer
Brief Summary: The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.


Options:
A: Inclusion Criteria:

* Prostate cancer in the early stage of disease
* Prostate removed and/or radiation therapy to the prostate area

Exclusion Criteria:

* Previous systemic therapy for prostate cancer
* Previous history of another form of cancer (not prostate) within 5 years of study start.
B: Inclusion Criteria:

* Clinical diagnosis of non-metastatic cancer of the prostate gland
* Patient to be 18 years and above

Exclusion Criteria:

* Previous systemic therapy for prostate cancer
* Previous history of another form of cancer (not prostate) within 5 years of study start.
C: Inclusion Criteria:

* Clinical diagnosis of non-metastatic cancer of the prostate gland
* Patient to be 18 years and above

Exclusion Criteria:

* Previous systemic therapy for prostate cancer
* Previous history of another form of cancer (not prostate) within 5 years of study start.
D: Inclusion Criteria:

* Osteoporotic patients (T score ≤ -2.5) with advanced prostate cancer requiring hormone manipulation, due to biochemical relapse following either radical prostatectomy, radiotherapy, brachytherapy, or biochemical progression after initially being observed with prostate cancer.

Exclusion Criteria:

* Severe hepatic insufficiency, with bilirubin above reference range
* Previous systemic therapy for prostate cancer
* Radiotherapy within 6 months
* Previous other invasive malignancies
* Any severe concomitant disease.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Diffusion of Clinical Pathways for the Implementation of Effective and Appropriate Care
Brief Summary: The purposes of this study are to determine whether clinical pathways: 1)improve the quality of the care provided to patients affected by stroke in terms of clinical outcomes, efficiency continuity of care and patients' satisfaction; 2) facilitate the use of evidence based medicine in clinical practice.


Options:
A: Inclusion Criteria:

* Principal diagnosis of Ischemic Stroke (ICD9CM code 434.91)

Exclusion Criteria:

* Transient cerebral ischemia (ICD9CM code 435.9)
* Intracerebral hemorrhage (ICD9CM codes 431.xx)
B: Inclusion criteria:

* Older than 18
* Ischemic stroke within 7 days of the index event
* Direct admission based on physician evaluation or arrival through the emergency department
* Ability of patient or legally authorized representative to provide informed consent for 3, 6,and 12 months after initial symptom onset
* Eligible events were confirmed by brain ct or mri within7 days after the onset of symptoms

Exclusion criteria:

* Patients refuse to participate in this study
C: Inclusion Criteria:

* Randomized, controlled subjects were VA inpatient rehabilitation teams. Secondary data included telephone surveys from discharged patients treated by the rehabilitation teams.

Exclusion Criteria:

* VA sites which did not submit data to the VA-FSOD - the national functional outcomes database
D: Inclusion Criteria:

* Occupational therapists and physical therapists with a minimum of 1 year clinical experience, working in an in-patient stroke rehabilitation centre in Canada.
* Sites will be eligible if they do not have an existing format knowledge translation initiative directed at enhancing practice in mobility training, have at least 10 people with stroke on their unit on a regular basis, and have an interdisciplinary team consisting of 2-3 occupational therapists and 2-3 physical therapists.
* Patients with a documented walking deficit (documented in patient's chart) and which are on the caseload of a minimum of one participating clinician.

Exclusion Criteria:

* Occupational or physical therapists who are currently participating in another knowledge translation study directed at enhancing practice in mobility training.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Diffusion of Clinical Pathways for the Implementation of Effective and Appropriate Care
Brief Summary: The purposes of this study are to determine whether clinical pathways: 1)improve the quality of the care provided to patients affected by stroke in terms of clinical outcomes, efficiency continuity of care and patients' satisfaction; 2) facilitate the use of evidence based medicine in clinical practice.


Options:
A: Inclusion Criteria:

* Principal diagnosis of Ischemic Stroke (ICD9CM code 434.91)

Exclusion Criteria:

* Transient cerebral ischemia (ICD9CM code 435.9)
* Intracerebral hemorrhage (ICD9CM codes 431.xx)
B: Inclusion criteria:

* Older than 18
* Ischemic stroke within 7 days of the index event
* Direct admission based on physician evaluation or arrival through the emergency department
* Ability of patient or legally authorized representative to provide informed consent for 3, 6,and 12 months after initial symptom onset
* Eligible events were confirmed by brain ct or mri within7 days after the onset of symptoms

Exclusion criteria:

* Patients refuse to participate in this study
C: Inclusion Criteria:

* An acute cerebrovascular event (ischemic stroke or intra-cerebral bleeding (ICB)) with the signs and symptoms of an acute stroke according to the World Health Organisation definition of acute stroke14 within the last 12 hours without the need or possibility of a neurosurgical intervention
* No thrombolytic therapy within the first 3 hours (in order to allow the correct comparison with the Swiss cohort of the IST trial
* The informed consent of the patient or, if not possible, of the relatives
* Living at home before the event
* Lack of participation in another trial.

Exclusion Criteria:

* Thrombolytic therapy within the first 3 hours (in order to allow the correct comparison with the Swiss cohort of the IST trial
* No informed consent of the patient or, if not possible, of the relatives
* Not living at home before the event
* Participation in another trial (26 patients were excluded because of TIA with full recovery within 24 hours after the event)
D: Inclusion Criteria:

* Occupational therapists and physical therapists with a minimum of 1 year clinical experience, working in an in-patient stroke rehabilitation centre in Canada.
* Sites will be eligible if they do not have an existing format knowledge translation initiative directed at enhancing practice in mobility training, have at least 10 people with stroke on their unit on a regular basis, and have an interdisciplinary team consisting of 2-3 occupational therapists and 2-3 physical therapists.
* Patients with a documented walking deficit (documented in patient's chart) and which are on the caseload of a minimum of one participating clinician.

Exclusion Criteria:

* Occupational or physical therapists who are currently participating in another knowledge translation study directed at enhancing practice in mobility training.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Misoprostol for Treatment of Incomplete Abortion
Brief Summary: This study aims to compare the efficacy, side effects profile and acceptability of a single dose of 600mcg misoprostol taken orally compared to standard surgical treatment as per local protocols for the treatment of incomplete abortion.


Options:
A: Inclusion Criteria:

* past or present history of vaginal bleeding during pregnancy
* open cervical os
* evidence of incomplete abortion with substantial debris in the uterus (if using ultrasound)
* surgical evacuation of the uterus would be advised as course of action if misoprostol was not available
* generally in good health
* woman lives or works within one hour of study site
* woman willing to provide contact information for follow up purposes
* informed consent given

Exclusion Criteria:

* contraindications to study drug
* uterine size larger than 12 weeks LMP
* signs of severe infection
B: Inclusion Criteria:

* between 5 and 12 completed weeks gestation
* 18 years or older
* hemodynamically stable
* confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)
* willing and able to give informed consent

Exclusion Criteria:

* diagnosis of incomplete or inevitable abortion (absent gestational sac and/or active bleeding, open cervical os)
* contraindication to mifepristone (chronic corticosteroid administration, adrenal disease)
* contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, or known allergy to prostaglandin)
* cardiovascular disease (angina, valvular disease, arrhythmia, or cardiac failure)
* most recent hemoglobin \<9.5 g/dL
* diagnosis of porphyria
* known clotting defect or receiving anticoagulants
* pregnancy with an intrauterine device (IUD) in place
* breastfeeding during the first 7 days of study participation
* unwilling to comply with the study protocol and visit schedule
* any evidence of viable pregnancy
* possibility of ectopic pregnancy
* known or suspected pelvic infection
* concurrent participation in any other interventional trial
C: Inclusion Criteria:

* nonviable intrauterine pregnancy with retained gestational sac in the uterus
* the embryo if visible 5 to 35 mm without a heart beat
* vaginal bleeding
* circulatory stable
* hemoglobin at least 80 g/L

Exclusion Criteria:

* contraindications against misoprostol
D: Inclusion Criteria:

* no contraindications to misoprostol
* uterine size was not larger than 12 weeks
* there were no signs of severe infection
* haemodynamically stable
* in general good health
* willing to provide contact information

Exclusion Criteria:

* an IUD in place
* ectopic pregnancy
* aged below 18 years and had no accompanying adult to provide informed consent

Answer: A